Tirzepatide Weight Loss Medication

At My Concierge MD, we provide Tirzepatide injection such as Mounjaro and Zepbound, medications used to treat type 2 diabetes. Mounjaro for weight loss increases insulin levels in the body and decreases glucagon, which controls the amount of glucose made by the liver.

Changes in diet and exercise are often recommended in combination with this medication. Mounjaro is a once-weekly injection that comes in six different strengths to lower the risk of side effects.

At My Concierge MD, we also offer Wegovy (Semaglutide), another once-weekly injectable prescription medication that can assist with long-term weight management by slowing stomach emptying, reducing appetite, and increasing insulin release.

Obesity is a metabolic disease that increases the risk of chronic diseases such as type 2 diabetes, hypertension, and cardiovascular disease. So, it’s important to address obesity as a public health concern and promote healthy lifestyle changes. Obesity is characterized by excessive body fat accumulation, usually resulting from a combination of genetic, behavioral, and environmental factors.

What is Tirzepatide Weight Loss Medication?

Mounjaro is in a class of medications called tirzepatides. These medications were FDA-approved for weekly injection by patients with type 2 diabetes to lower blood sugars.

How does Tirzepatide Weight Loss Work?

This diabetes medication works by activating the GIP and GLP-1 receptors. These receptors help decrease blood sugar and increase insulin secretion as well as decrease hunger and appetite. They also help decrease the GI motility so you feel fuller faster when you eat.

In addition to controlling blood sugar, Tirzepatide has also been shown in clinical trials to be useful for weight loss, although currently, it is not an FDA-approved weight loss drug. Tirzepatide is only indicated for adults and should be used with diet and physical activities.

Is Mounjaro approved for weight loss?

Mounjaro is approved by the FDA to treat type 2 diabetes. There is a new tirzepatide called Zepbound that was approved by the FDA in November of 2023 for weight loss, but the active ingredients of the medications are the same. Both Zepbound and Mounjaro work the same way in regards to decreasing blood sugars and decreasing appetite.

Mounjaro Shortage

Due to the effectiveness of these medications and the off label use of Mounjaro for weight loss, there has been a shortage of these medications on the market. Many of the pharmacies are not able to get enough supply of the medication to meet the demand. Due to the shortage and the need of these medications, compounding pharmacies have been able to compound these drugs.

How To Get Mounjaro Injections For Weight Loss

Contact us at 310-299-8959 to schedule an in office consult or virtual consult

or Book Online to receive your prescription of Mounjaro or other Semaglutide or Tirzepatide for weight loss.

• Virtual Consult with MD & Nutritionist $450
• 3 Month Supply of the best compounded semaglutide injection  $750 ( Special Pricing) 
• Follow Ups $200
• Lose 10 – 20% of body fat safely and effectively

What does Tirzepatide Weight Loss Medication do to the body?

Tirzepatide class of medications such as Mounjaor causes weight loss through multiple mechanisms. It signals to the brain that you’re full, which helps in eating less. Tirzepatide also slows down food movement through the stomach, making you feel full for extended periods.

Studies have shown that patients with type 2 diabetes treated with Tirzepatide lost an average of 5.5 kg to 11 kg in some cases. With the highest dose of tirzepatide, 15 mg, the average body weight reduction was 22.5%, resulting in a loss of 23.6 kilograms or 52.0 pounds. The result is comparable to most types of bariatric surgery.

Therefore, Tirzepatide is not only helpful in lowering blood sugar levels but also a promising option for people struggling with obesity.

What are Tirzepatide medications like Mounjaro made from?

Tirzepatide is made from glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, which are used to treat type 2 diabetes mellitus as a single therapy or with other diabetes medicines. Still, it is not approved for treating type-1 diabetes mellitus and has not been studied in patients with pancreatitis. Tirzepatide is also known as Mounjaro®.

Who can take Mounjaro for weight loss?

People with Type 2 diabetes may experience weight loss as a side effect of taking Mounjaro. However, currently, Tirzepatide or Mounjaro is not FDA-approved for weight loss. Some healthcare providers may prescribe it off-label for weight loss in people without diabetes. The efficacy and safety of Tirzepatide for weight loss in people with obesity are not known but to date they have shown to have great weight loss properties and safe while under the supervision of medical professional.

How much weight do you lose on Mounjaro?

On tirzepatide, participants experienced weight loss ranging from 50-57% to 78-84% across the 10-mg and 15-mg dose groups. Over 72 weeks, patients treated with tirzepatide had an average weight loss of 15-20% of their starting body weight or around 52 pounds.

Compared to the weight loss drugs Wegovy and Saxenda, tirzepatide resulted in a greater reduction in body weight. While not officially approved for weight loss, studies show that participants on tirzepatide lost an average of 5.5-11 kg (12-25 lbs).

Is Mounjaro prescription only?

Yes, Mounjaro is a prescription-only medicine for adults with type 2 diabetes and should only be used with diet and exercise. It is not approved for weight management by the FDA and cannot be used in people with type 1 diabetes or those with inflammation of the pancreas. Do not take a tirzepatide or other medicines without discussing it with your doctor.

Is Tirzepatides ( Mounjaro) approved by the FDA?

Yes, tirzepatide is approved by the Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and obesity treatment. The approval was announced on May 13, 2022.

What is the price of Tirzepatide for weight loss?

The price of tirzepatide for weight loss is around $989.32 at CVS, Walgreens, and other pharmacies. If the FDA confirms the drug’s effectiveness, a “fair” price for tirzepatide could be around $13,000 annually or around $1,100 a month.

However, if tirzepatide is approved for weight loss, it could become the best-selling obesity drug. Those treated with tirzepatide had an average weight loss of 15% to 20% of their starting body weight over 72 weeks, while those taking the placebo only had an average of 3% weight loss.

Side effects of Tirzepatide

Gastrointestinal Effects: Common GI-related side effects may include nausea, vomiting, diarrhea, and abdominal pain. Symptoms are typically mild to moderate and can improve with time.

Hypoglycemia: Tirzepatide can reduce blood glucose levels and potentially cause hypoglycemia which includes dizziness, sweating, confusion, or hunger.

Thyroid Tumors: In animal studies, tirzepatide has been associated with developing thyroid tumors. However, further research is needed to understand the relevance of this finding in humans.

Kidney Problems: Occasionally, acute kidney injury can occur due to dehydration caused by gastrointestinal losses. This has been seen in both healthy and patients with existing chronic renal disease. Thus, regular monitoring of hydration levels is recommended as a preventative measure.

Pancreatitis: It has a similar risk level for acute pancreatitis as GLP-1 agonist medications (Semaglutide, Ozempic, etc.). Patients should be aware that severe abdominal pain could indicate the onset of this condition and seek care at their local emergency department if needed. Furthermore, asymptomatic elevations in lipase and amylase may also occur with tirzepatide use.

Hepatobiliary: Tirzepatide therapy has been associated with hepatobiliary side effects, such as gallstones and cholecystitis. In some cases, these can cause abdominal pain, nausea, or vomiting, while more severe symptoms may occur due to gallbladder inflammation (cholecystitis).

Ocular: Patients with preexisting diabetic retinopathy should be aware that their vision symptoms may temporarily worsen due to improved glycemic control when using Tirzepatide, a GLP-1 receptor agonist. Any changes in vision during treatment must be discussed promptly with a doctor.

Endocrine: With its potential for hypoglycemia, this medication should be taken cautiously and monitored closely. Patients may experience dose-dependent risks, which could prove more severe in those on insulin or sulfonylureas; thus, regular blood glucose checks are strongly advised to ensure the safety and well-being of users.

Injection Site Reactions: Some individuals may experience injection site reactions, such as redness, swelling, or itching at the injection site.

Tirzepatide Injections near me

My Concierge, MD, Beverly Hills, offers the best tirzepatide injections near me in Beverly Hills but can also come to your home or office throughout the Los Angeles area. We serve patients near Beverly Hills, Bel Air, West Hollywood, Santa Monica, West Los Angeles, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, Redondo Beach, Downtown Los Angeles, Encino, Woodland Hills, Sherman Oaks, Calabasas, Burbank, Glendale, Hidden Hills, Agoura Hills, Northridge, North Hollywood, Topanga, Canoga Park, Reseda, Valley Glen, Chatsworth, West Hills, Winnetka, Universal City, Silverlake, Echo Park, and many more.

Reference:

1. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018;71(1):69-84. doi:10.1016/j.jacc.2017.11.011

2. Jastreboff AM, Aronne LJ, Ahmad NM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. 2022;387(3):205-216. doi:https://doi.org/10.1056/nejmoa2206038

3. Tirzepatide (Mounjaro) for type 2 diabetes. Med Lett Drugs Ther. 2022;64(1654):105-107.

4. Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020;45 Suppl 1(Suppl 1):43-60. doi:10.1111/jcpt.13225

5. Tirzepatide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; June 20, 2022.

6. Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care. 2021;44(1):290-296. doi:10.2337/dc20-1815

7. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315